利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.023 秒)

    Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
    5.
    发明授权
    Indole, azaindole and related heterocyclic N-substituted piperazine derivatives 有权
    吲哚，氮杂吲哚和相关杂环N-取代的哌嗪衍生物

    公开(公告)号：US08039486B2

    公开(公告)日：2011-10-18

    申请号：US12028189

    申请日：2008-02-08

    申请人： Kap-Sun Yeung ,  Michelle E. Farkas ,  John F. Kadow ,  Nicholas A. Meanwell ,  Malcolm Taylor ,  David Johnston ,  Thomas Stephen Coulter ,  J. J. Kim Wright

    发明人： Kap-Sun Yeung ,  Michelle E. Farkas ,  John F. Kadow ,  Nicholas A. Meanwell ,  Malcolm Taylor ,  David Johnston ,  Thomas Stephen Coulter ,  J. J. Kim Wright

    IPC分类号： A61K31/04 ,  C07D215/38

    CPC分类号： C07D413/14 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D491/04

    摘要： This invention provides compounds of Formula I, including pharmaceutically acceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein: Z is Q is selected from the group consisting of m is 2; A is selected from the group consisting of cinnolinyl, napthyridinyl, quinoxalinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, azabenzofuryl, and phthalazinyl each of which may be optionally substituted with one or two groups independently selected from methyl, methoxy, hydroxy, amino and halogen; and —W— is

    摘要翻译： 本发明提供具有药物和生物影响性质的式I化合物，包括其药学上可接受的盐，其药物组合物和使用方法。 这些化合物具有独特的抗病毒活性，无论是单独使用还是与其他抗病毒药，抗感染剂，免疫调节剂或HIV进入抑制剂组合使用。 更具体地说，本发明涉及艾滋病毒和艾滋病的治疗。 式I的化合物具有下式：其中：Z为Q选自m为2; A选自噌啉基，萘啶基，喹喔啉基，吡啶基，嘧啶基，喹啉基，异喹啉基，喹唑啉基，氮杂苯并呋喃基和酞嗪基，其各自可以任选被一个或两个独立地选自甲基，甲氧基，羟基，氨基 和卤素; 和-W-是

    Pyrrolopyrimidines for pharmaceutical compositions
    7.
    发明授权
    Pyrrolopyrimidines for pharmaceutical compositions 有权
    用于药物组合物的吡咯并嘧啶

    公开(公告)号：US08697713B2

    公开(公告)日：2014-04-15

    申请号：US12373224

    申请日：2007-07-10

    申请人： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

    发明人： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

    IPC分类号： A01N43/90 ,  A61K31/519 ,  C07D487/00

    CPC分类号： C07D487/04

    摘要： The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

    摘要翻译： 本发明涉及通式（1）的新型吡咯并嘧啶化合物和包含所述吡咯并嘧啶化合物的药物组合物。 此外，本发明涉及本发明的吡咯并嘧啶化合物用于制备药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。

    PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS
    9.
    发明申请
    PYRROLOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS 有权
    药物组合物的吡咯并吡啶

    公开(公告)号：US20100105708A1

    公开(公告)日：2010-04-29

    申请号：US12373224

    申请日：2007-07-10

    申请人： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

    发明人： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

    IPC分类号： A61K31/519 ,  C07D487/04 ,  A61P3/00 ,  A61P29/00

    CPC分类号： C07D487/04

    摘要： The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

    摘要翻译： 本发明涉及通式（1）的新型吡咯并嘧啶化合物和包含所述吡咯并嘧啶化合物的药物组合物。 此外，本发明涉及本发明的吡咯并嘧啶化合物用于制备药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。